iOnctura reaches new clinical milestones in uveal melanoma
Completed Phase I DIONE-01 study demonstrates clinical activity and long-term safety of roginolisib, a unique allosteric modulator of PI3Kδ
Patients with uveal melanoma showed a doubling of overall survival compared to historical controls
Site activation ongoing for randomized Phase II OCULE-01 study in uveal melanoma
Geneva, Switzerland and Amsterdam, The Netherlands, 11 Dec 2024 – iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today provides a clinical update on its lead asset, roginolisib. Results from the completed Phase I DIONE-01 study are due to be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) annual congress tomorrow, 12 December at 12:30 CET (presentation 164P).
